Immutep Faces Securities Class Action Over Clinical Trial Claims

The complaint filed against Immutep, traded on the NASDAQ as IMMP, centers on alleged violations of the Securities Exchange Act of 1934. Specifically, the suit claims the company issued false and misleading statements to the market. While a January 30, 2026, SEC filing touted strong operational progress for the TACTI-004 trial, the lawsuit asserts that leadership was already aware the trial would fall short of its primary efficacy goals.

The DJS Law Group is currently organizing the action and seeking potential lead plaintiffs. Shareholders wishing to participate in the recovery effort must act before the July 6, 2026, deadline. Legal representatives note that serving as a lead plaintiff is not a prerequisite for individual investors to participate in any eventual settlement or judgment resulting from the case.